• For individuals between the ages of 2.5-45 years with a first-degree relative (parent, child, sibling) with type 1 diabetes
• For individuals between the ages of 2.5-20 years with a second-degree relative (grandparent, aunt, uncle, niece, nephew, cousin or half-sibling) with type 1 diabetes

Purpose: To identify individuals at-risk for T1D and offer close monitoring for disease progression as well as potential prevention study opportunities.

For more information visit TrialNet on the web. 

Study Cordinator:  Juanita O'Brian, NRCMA

Contact: usfdiabetesresearchc@usf.edu

• For individuals > 6 years
• Positive for two or more diabetes-related auto-antibodies
• Normal Glucose Tolerance

Purpose:  To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Coordinator: Juanita O'Brian, NRCMA

Contact: usfdiabetesresearchc@usf.edu

• For individuals > 3 years old
• Positive for two or more diabetes-related auto-antibodies
• Normal Glucose Tolerance

Purpose: To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Coordinator: Juanita O'Brian, NRCMA

Contact: usfdiabetesresearchc@usf.edu

• For individuals > 12 years old
• Diagnosed with Type 1 Diabetes within 150 days

Purpose: To preserve insulin production by preventing beta cell destruction in individuals newly diagnosed with T1D.

Study Coordinator: Ponja Hemphill, RN

Contact: usfdiabetesresearchc@usf.edu

• For Individuals ages 8-17
• Diagnosed with T1D within 42 days
• Up to date on immunizations

Purpose: To determine whether an investigational drug called Teplizumab may help preserve insulin production in children and adolescents who were recently diagnosed with Type 1 Diabetes

Study Coordinator: Ponja Hemphill, RN

Contact: usfdiabetesresearchc@usf.edu

• For individuals ages 2-17
• Diagnosed with type 1 diabetes or insulin-requiring type 2 diabetes
• Has NOT used a Continuous Glucose Monitoring device (CGM) in the last year

Purpose: To evaluate the safety of non-adjunctive CGM use in CGM naive participants, by assessing the number of hypoglycemic and diabetic ketoacidosis (DKA) events with use of CGM 

Study Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/BASIC

Contact: usfdiabetesresearchc@usf.edu

• For individuals ages 10-17
• Diagnosed with type 2 diabetes for at least 12 weeks
• Additional eligibility criteria will be reviewed with you by the study coordinator

Purpose: To test the safety and effectiveness of Linagliptin in combination with Empagliflozin (FDA approved for treatment of type 2 adults) in pediatric type 2 patients.

Study Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/BASIC

Contact: usfdiabetesresearchc@usf.edu